Yoshihiko Tasaki

8PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ReproductionImmunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 02, 2026
Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.

|May 04, 2026
Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

|Jan 13, 2026
Integrating pharmacokinetic modeling and wearable-derived physiological data to assess pain intensity in patients with advanced urologic cancer.

Yosuke Sugiyama, Yoshihiko Tasaki, Yoshihisa Mimura

|Jun 27, 2024
Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.

Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa

|Apr 29, 2024
Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.

Yoshihiko Tasaki, Nanami Ito, Yoshihisa Mimura

|Nov 21, 2023
Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.

Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto

Pageof 2

Frequent Collaborators

6 joint publications

Taku Naiki

5 joint publications

Yosuke Sugiyama

5 joint publications

Takahiro Yasui

3 joint publications

Toshiharu Morikawa